| 郑 霞,魏 莉,朱 烨,邵 娟,王 博.杉醇联合奈达铂新辅助治疗局部晚期宫颈癌的临床效果研究[J].现代生物医学进展英文版,2018,(22):4317-4320. |
| 杉醇联合奈达铂新辅助治疗局部晚期宫颈癌的临床效果研究 |
| Clinical Efficacy of Paclitaxel Combined with Nedaplatin in the Treatment of Locally Advanced Cervical Cancer |
| Received:February 28, 2018 Revised:March 24, 2018 |
| DOI：10.13241/j.cnki.pmb.2018.22.026 |
| 中文关键词: 紫杉醇 奈达铂 新辅助化疗 局部晚期宫颈癌 临床疗效 |
| 英文关键词: Paclitaxel Nedaplatin Neoadjuvant chemotherapy Locally advanced cervical cancer Clinical efficacy |
| 基金项目:陕西省社会发展科技攻关项目（2015SF134） |
|
| Hits: 462 |
| Download times: 281 |
| 中文摘要: |
| 摘要 目的：探讨紫杉醇联合奈达铂治疗局部晚期宫颈癌患者的近远期疗效。方法：选择2010年3月～2011年8月在我院进行诊治的局部晚期宫颈癌患者67例，按住院序号分为观察组33例和对照组34例。对照组单纯给予腹腔镜宫颈癌根治手术治疗，观察组联合给予新辅助化疗(静脉注射紫杉醇135 mg/m2以及奈达铂75 mg/m2)。比较两组的临床治疗效果，术后的宫旁累及阳性率、阴道切缘阳性率、淋巴结转移阳性率以及脉管浸润阳性率。对两组患者进行3年的随访，比较两组的复发率、转移率以及3年生存率。结果：观察组的近期治疗有效率为93.94 %(31/33)，明显高于对照组的70.59 %(24/34)(P<0.05)；与对照组相比，观察组术后宫旁累及阳性率、阴道切缘阳性率、淋巴结转移阳性率、脉管浸润阳性率均明显较低(P<0.05)；经过3年的随访，观察组的复发率以及转移率明显低于对照组(P<0.05)，3年生存率明显高于对照组(P<0.05)。结论：紫杉醇联合奈达铂新辅助治疗局部晚期宫颈癌的近期疗效以及远期疗效明显优于单纯给予腹腔镜宫颈癌根治手术治疗。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of paclitaxel combined with nedaplatin in the treatment of locally advanced cervical cancer. Methods: 67 cases of patients with locally advanced cervical cancer who were treated in our hospital from March 2010 to August 2011 were selected and divided into two groups, 33 cases in the observation group, 34 cases in the control group. The control group was treated with laparoscopic radical surgery alone, while the observation group was given neoadjuvant chemotherapy (intravenous paclitaxel 135 mg/m2 and nedaplatin 75 mg/m2). The clinical effects, positive rates of vaginal margins, lymph node metastasis, uterine involvement and vascular invasion were observed and compared between two groups. Both groups of patients were followed up for 3 years, the recurrence rate, metastasis rate and long-term survival rate of two groups were observed and compared. Results: After treatment, the effective rate of observation group was 93.94 %(31/33), which was significantly higher than that of the control group[70.59 %(24/34)](P<0.05); the positive rate of vaginal margins, lymph node metastasis, uterine involvement and vascular invasion of observation group were significantly lower than those of the control group(P<0.05). After 3 years of follow-up, it was found that the recurrence rate and metastasis rate of observation group were significantly lower than those of the control group (P<0.05), and the 3-year survival rate of observation group was significantly higher than that of the control group(P<0.05). Conclusion: The short-term efficacy and long-term efficacy of paclitaxel combined with nedaplatin in the treatment of locally advanced cervical cancer were better than those of laparoscopic radical surgery alone for cervical cancer. |
|
View Full Text
View/Add Comment Download reader |
| Close |
